This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Immunotherapy is an essential component of cancer care and expands the treatment possibilities for patients. Immune checkpoint inhibitors are among the most promising drugs but are associated with toxicities.
We propose an integrated and adaptable approach to improve patient care and clinical outcomes through analgesia and light sedation, initiated early during an episode of critical illness and as a priority of care.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life.
Dyspnoea is described as difficult or laboured breathing and is a frequent symptom in advanced cancer patients, with the highest prevalence in lung cancer. Dyspnoea has been demonstrated to be one of the most distressing...
ESMO Clinical Practice Guidelines for management of oral and gastrointestinal mucositis includes chapters on the definition of mucositis, its incidence and associated complications, risk factors...
ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.